LEXX Valuation

Lexaria Bioscience Corp

Add to Watchlist

Advanced Chart

1.080

0(0.000%)1D

LEXX Relative Valuation

LEXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LEXX is overvalued; if below, it's undervalued.

Historical Valuation

Lexaria Bioscience Corp (LEXX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.08 is considered Undervalued compared with the five-year average of -3.25. The fair price of Lexaria Bioscience Corp (LEXX) is between 13.88 to 56.15 according to relative valuation methord. Compared to the current price of 1.05 USD , Lexaria Bioscience Corp is Undervalued By 92.44%.

Relative Value

Fair Zone

13.88-56.15

Current Price：1.05

92.44%

Undervalued

-1.74

Trailing

Forward

0.00

EV/EBITDA

Lexaria Bioscience Corp. (LEXX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.96. The thresholds are as follows: Strongly Undervalued below -4.82, Undervalued between -4.82 and -2.89, Fairly Valued between 0.98 and -2.89, Overvalued between 0.98 and 2.91, and Strongly Overvalued above 2.91. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.40

EV/EBIT

Lexaria Bioscience Corp. (LEXX) has a current EV/EBIT of -1.40. The 5-year average EV/EBIT is -1.99. The thresholds are as follows: Strongly Undervalued below -6.74, Undervalued between -6.74 and -4.36, Fairly Valued between 0.39 and -4.36, Overvalued between 0.39 and 2.76, and Strongly Overvalued above 2.76. The current Forward EV/EBIT of -1.40 falls within the Historic Trend Line -Fairly Valued range.

1.08

Lexaria Bioscience Corp. (LEXX) has a current PS of 1.08. The 5-year average PS is 44.67. The thresholds are as follows: Strongly Undervalued below -9.67, Undervalued between -9.67 and 17.50, Fairly Valued between 71.84 and 17.50, Overvalued between 71.84 and 99.01, and Strongly Overvalued above 99.01. The current Forward PS of 1.08 falls within the Undervalued range.

0.00

P/OCF

Lexaria Bioscience Corp. (LEXX) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.09. The thresholds are as follows: Strongly Undervalued below -11.50, Undervalued between -11.50 and -7.29, Fairly Valued between 1.12 and -7.29, Overvalued between 1.12 and 5.33, and Strongly Overvalued above 5.33. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Lexaria Bioscience Corp. (LEXX) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.55. The thresholds are as follows: Strongly Undervalued below -5.80, Undervalued between -5.80 and -3.68, Fairly Valued between 0.57 and -3.68, Overvalued between 0.57 and 2.69, and Strongly Overvalued above 2.69. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Lexaria Bioscience Corp (LEXX) has a current Price-to-Book (P/B) ratio of 3.80. Compared to its 3-year average P/B ratio of 3.53 , the current P/B ratio is approximately 7.89% higher. Relative to its 5-year average P/B ratio of 3.49, the current P/B ratio is about 8.90% higher. Lexaria Bioscience Corp (LEXX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -35.91%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -28.85% , the current FCF yield is about -100.00% lower.

3.80

P/B

Median3y

3.53

Median5y

3.49

-42.23

FCF Yield

Median3y

-35.91

Median5y

-28.85

Competitors Valuation Multiple

The average P/S ratio for LEXX's competitors is 1.30, providing a benchmark for relative valuation. Lexaria Bioscience Corp Corp (LEXX) exhibits a P/S ratio of 1.08, which is -17.10% above the industry average. Given its robust revenue growth of 107.14%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LEXX.O

Lexaria Bioscience Corp

CASI Pharmaceuticals Inc

Moleculin Biotech Inc

Performance Decomposition

Market capitalization of LEXX decreased by 48.08% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 84.00K to 174.00K.

The secondary factor is the Margin Expansion, contributed 2.56%to the performance.

Overall, the performance of LEXX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

107.14%

84.00K → 174.00K

Revenue Growth

2.56%

-2.12K → -2.18K

Margin Expansion

-157.78%

2.79 → -1.61

P/E Change

-48.08%